Patterns of HIV-1 Viral Load Suppression and Drug Resistance During the Dolutegravir Transition: A Population-based Longitudinal Study. [PDF]
Martin MA +22 more
europepmc +1 more source
Combined injectable regimens in treatment-experienced HIV/AIDS patients at a southern academic medical center: a case series. [PDF]
Burton HJ +4 more
europepmc +1 more source
M184V: The Major Determinant of Cooperative ISL Resistance When in Combination with Multiple TAM2 Mutations in HIV-1 Subtype C. [PDF]
Nel K, Papathanasopoulos MA, Basson AE.
europepmc +1 more source
The therapeutic potential of transposable element activity modulation. [PDF]
Morelli G +3 more
europepmc +1 more source
Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta-analysis. [PDF]
Mahanani MR +7 more
europepmc +1 more source
Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV. [PDF]
Mason J +11 more
europepmc +1 more source
Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort. [PDF]
Ceccarelli M +14 more
europepmc +1 more source
Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study. [PDF]
Cheng W +8 more
europepmc +1 more source
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA. [PDF]
Diamond TL +14 more
europepmc +1 more source
Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. [PDF]
Bello G +25 more
europepmc +1 more source

